Cargando…
Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes
HER2+ breast cancer (BC) is an aggressive subtype representing a genetically and biologically heterogeneous group of tumors resulting in variable prognosis and treatment response to HER2-targeted therapies according to estrogen (ER) and progesterone receptor (PR) expression. The relationship with an...
Autores principales: | Orrù, Sandra, Pascariello, Emanuele, Sotgiu, Giovanni, Piras, Daniela, Saderi, Laura, Muroni, Maria Rosaria, Carru, Ciriaco, Arru, Caterina, Mocci, Cristina, Pinna, Giampietro, Barbara, Raffaele, Cossu-Rocca, Paolo, De Miglio, Maria Rosaria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773834/ https://www.ncbi.nlm.nih.gov/pubmed/35052843 http://dx.doi.org/10.3390/biomedicines10010164 |
Ejemplares similares
-
Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype
por: Orrù, Sandra, et al.
Publicado: (2023) -
Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype
por: Angius, Andrea, et al.
Publicado: (2020) -
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
por: Arru, Caterina, et al.
Publicado: (2021) -
A Portrait of Intratumoral Genomic and Transcriptomic Heterogeneity at Single-Cell Level in Colorectal Cancer
por: Angius, Andrea, et al.
Publicado: (2021) -
Deciphering clinical significance of BCL11A isoforms and protein expression roles in triple-negative breast cancer subtype
por: Angius, Andrea, et al.
Publicado: (2022)